Abstract: A device (250) for estimating the risk of a future hypoglycemic event for a subject with a standing insulin regimen (206), wherein the standing insulin regimen comprises one or more types of insulin medicament dosage regimen (208), wherein each of the one or more types of insulin medicament dosage regimen (208) comprises a type of insulin medicament (210) defining one or more types of insulin medicaments. Using the evaluation of a glucose concentration, a first time derivative and an insulin on board for the subject in a current metabolic state, and the evaluation of a glucose concentration, a first derivative and a historical insulin on board to estimate a hypoglycemic risk measure.

Abstract: A drug delivery device is provided comprising a housing having an exterior surface, drug ex-pelling means comprising an indicator member arranged to move corresponding to an action performed on or by the drug delivery device, and a carrier foil on which is formed or mounted an energy source, electronically controlled communication means, and a processor adapted to (i) receive input from the drug delivery device indicative of indicator member movement and (ii) control the communication means. The flexible carrier foil is mounted on the exterior of the housing, and the flexible carrier foil is covered at least in part by a sealing foil covering directly or indirectly the thereon formed or mounted components, whereby a sealed interior space for the components formed or mounted on the flexible carrier foil is formed between the housing exterior surface and the sealing foil.

Abstract: The present invention provides a drug injection device (100) comprising a first element (140) and a second element (103) configured to undergo unidirectional movement relative to each other corresponding to an action performed on or by the drug injection device (100), wherein the first element (140) comprises a plurality of serially disposed protrusions (143), wherein the second element (103) comprises first and second deflectable transducers (103a/153a, 103b/153b) configured for sequentially cooperating with the plurality of protrusions (143), and wherein a processor (151) is electrically connected with the first and second deflectable transducers (103a/153a, 103b/153b) to register activation signals, wherein the protrusion configuration is so disposed on the first element (140) and the first and second deflectable transducers (103a/153a, 103b/153b) are so disposed on the second element (103) that a second activation signal generated by the second deflectable transducer (103b/153b) is delayed relative to a f

Abstract: Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface (e.g., a surface of a tissue of a subject). The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage (e.g., interface with, inject into, anchor) with a surface (e.g., a surface of a tissue of a subject). In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject).

Abstract: Systems and methods are provided for adjusting long acting insulin medicament dosages for a subject. A plurality of timestamped glucose measurements of the subject and insulin injection data is obtained. A first glycaemic risk measures is determined, where the first risk glycaemic risk measure is i) glucose level variability across the glucose measurements, (ii) a variability in fasting glucose levels calculated from the glucose measurements, (iii) a minimum observed glucose measurement in the plurality of glucose measurements (iv) rate of change in ISF, or (v) adherence values. A fasting blood glucose target function is computed based upon at least the first glycaemic risk measure thereby obtaining an updated target fasting blood glucose level that is between a minimum and maximum target fasting blood glucose level. The long acting insulin medicament dosage is adjusted based upon the updated target fasting blood glucose level.

Abstract: A drug delivery device is provided comprising a drug-filled cartridge or means for receiving a drug-filled cartridge, and drug expelling means comprising expelling means for expelling an amount of drug from the cartridge, and an indicator member arranged to move corresponding to an action performed on or by the drug delivery device. The device further comprises an energy source, wireless communication means, sensor means adapted to detect movement of the indicator member, and a processor adapted to (i) receive input from the drug delivery device indicative of indicator member movement and (ii) control the communication means to transmit a data signal comprising coded information derived from received input from the sensor means, wherein the wireless communication means is in the form of a sound transducer.

Abstract: A method of verifying that a first unit and a second unit being mounted to each other are correctly paired, the first unit comprising a first visual identifier and the second unit comprising a second visual identifier, the method comprising the steps of (i) capturing an image of the first and second unit mounted to each, the image comprising both the first and the second visual identifier, and (ii) processing the captured image to (a) identify the first and the second visual identifier, and (b) determine whether the captured identifiers represent a predefined combination of visual identifiers to thereby verify the pairing.

Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.

Abstract: A geared drive arrangement comprises a stationary portion and a drive rod defining a reference axis and during operation being arranged to rotate and be moved axially corresponding to the reference axis, the drive rod comprising a first thread and a second thread. The drive arrangement further comprises a drive member comprising a drive thread in engagement with the drive rod first thread, and a nut portion comprising a propulsion thread arranged rotationally locked relative to the stationary portion and in engagement with the drive rod second thread. The drive member is arranged to rotate corresponding to the reference axis during operation, with the threaded engagement between the drive member and the drive rod causing the drive rod to rotate, and the threaded engagement between the nut portion and the drive rod causing the drive rod to move in the distal direction.

Abstract: The invention relates to a bispecific antibody comprising a first antigen-binding site capable of binding Factor VII(a) and a second antigen-binding site capable of binding TLT-1, pharmaceutical formulations comprising such bispecific antibodies and uses thereof.

Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.1% (w/w) phenol and above 6.4 mg/ml sodium chloride, their preparation, kits comprising such compositions as well as uses thereof.

Abstract: A drug delivery device comprising or adapted to receive a drug-filled cartridge, comprising a piston rod adapted to be rotated by a drive member to thereby move the piston rod distally during expelling, dose setting means allowing a user to simultaneously set a dose amount to be expelled, and a releasable locking mechanism adapted to rotationally lock the drive member relative to the housing during dose setting. The device further comprises release means actuatable between a dose setting mode and an expelling mode, wherein the locking mechanism is released when the release means is actuated from a dose setting mode to an expelling mode.

Abstract: A medication delivery device comprises an injection device having a reservoir comprising a medicament to be ejected, and a sensor arranged to detect an ejection of the medicament from the injection device, the sensor being arranged to output a signal comprising ejecting information, and a processor for collecting and storing the ejection information.

Abstract: A sensor assembly comprising a first rotary sensor part having a plurality of individual electrically conducting code segments arranged in a circumferential pattern, and a plurality of electrically conducting reference segments between the code segments, and a second rotary sensor part arranged rotationally relative to the first part a plurality of contact structures, each contact structure being arranged to be in contact with either a code segment or a reference segment depending on the rotational position between the first and second rotary sensor part. The contact structures are configured to engage and connect to different sensor segments as the first and second rotary sensor part rotate relative to each, the created connections being indicative of a rotational position between the first and second rotary sensor part. For a given rotational position, at least one contact structure engages a code segment and at least one contact structure engages a reference segment.

Abstract: The present invention relates to a handheld mechanical injection device by which set doses of a liquid medicament can be injected from a medical reservoir. The medicament is expelled through an injection needle by release of a power reservoir in the device, the power reservoir being fully or partially released by actuation of a user operable release member being positioned at or near an upper end of the injection device, the upper end being that end of the injection device which is opposite the injection needle.

Abstract: Systems and methods are provided for adjusting long acting insulin medicament dosages for a subject. A plurality of timestamped glucose measurements of the subject is obtained. A titration glucose level (246) is computed as a measure of central tendency (244, 268, 274) of a titration subset of small glucose measurements (240, 269, 273) identified within the timestamped glucose measurements, wherein the measure of central tendency represents a measure of small glucose measurements for the primary time window. A long acting insulin medicament dosage (216) is adjusted or maintained based upon the obtained titration glucose level (246).

Abstract: The invention relates to protein conjugates and in particular conjugates of more than two protein or polypeptides. The compounds include a trivalent linker moiety that enables efficient production of desired products.

Abstract: A needle cannula for an injection device, extends along a central axis and comprises: a) a skin piercing distal end (133b), b) a proximal end (133a) configured for penetrating a seal structure (102b) of a medicament container (102), and c) a sidewall extending between the skin piercing distal end (133b) and the proximal end (133a), wherein the proximal end (133a) is defined by an angled surface (134) pointing proximally, the angled surface (134) defining a leading portion (134.1) and a heel portion (134.2), and wherein the angled surface (134) comprises a surface portion (134a, 134b) at the heel portion (134.2) forming an angle (?1) between 50 to 75 degrees with respect to the central axis, and further comprises a surface portion (134c) at the leading portion (134.1) forming an angle (?2) between 60 to 85 degrees with respect to the central axis. An injection needle assembly for an injection device and an injection device comprising such assembly are further described.